Search results for "From ACP Journal Club"
Any of 4 screening options suggested for screen-naive adults 59 to 70 y with ≥ 3% 15-y risk for colorectal cancer
To balance shared decision making and population health in colorectal cancer screening, as called for in a recent guideline, a viable strategy could include universal, opt-out fecal immunochemical testing starting at age 50 years, a commentary in ACP Journal Club noted.
https://gastroenterology.acponline.org/archives/2020/03/27/11.htm
27 Mar 2020
In irritable bowel syndrome, fecal microbiota transplantation improved symptoms at 3 months
While fecal microbiota transplantation was effective in patients with moderate to severe irritable bowel syndrome in a randomized trial, long-term risks of the therapy remain uncertain, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/05/22/10.htm
22 May 2020
H. pylori treatment reduced risk for gastric cancer in patients with a family history of gastric cancer
While results of the trial support a test-and-treat screening approach for Helicobacter pylori in patients with a first-degree relative with gastric cancer, more research is needed before considering universal screening in this population, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/06/26/7.htm
26 Jun 2020
USPSTF recommends screening adults 18 to 79 years for hepatitis C virus infection with moderate certainty
An essential requirement of expanded screening is the availability of effective treatment, but randomized controlled trials to date have not shown clinical benefit of direct-acting antiviral therapy beyond sustained virologic response, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/07/24/7.htm
24 Jul 2020
In high-risk patients with acute upper GI bleeding, urgent vs. early endoscopy did not differ for 30-day mortality
While a randomized trial found no better outcomes with endoscopy within six hours of gastroenterology consult, “middle-of-the-night” endoscopy should still be considered for certain higher-risk patients who were excluded from the trial, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2020/08/28/7.htm
28 Aug 2020
H. pylori eradication therapy may reduce gastric cancer risk; rifabutin-based therapy effective in industry-sponsored trial
A meta-analysis suggested that, in addition to preventing progression, early Helicobacter pylori eradication therapy reduces gastric cancer risk, and a novel rifabutin-based therapy may offer physicians another option for initiating eradication treatment, an ACP Journal Club commentary on both studies said.
https://gastroenterology.acponline.org/archives/2020/09/25/9.htm
25 Sep 2020
In adults with severe acute GI bleeding, tranexamic acid did not reduce death due to bleeding at 5 days
Based on findings from a randomized trial, tranexamic acid is unlikely to confer additional benefit beyond the current standard of care in all patients with severe upper or lower GI bleeding, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2020/10/23/10.htm
23 Oct 2020
Daily aspirin for primary CVD prevention increased risk for major GI bleeding in healthy older adults
While aspirin is not recommended for primary prevention of cardiovascular disease (CVD) in most adults ages 70 years and older, more research is needed to assess its role in select high-risk populations of older adults, an ACP Journal Club commentary said.
https://gastroenterology.acponline.org/archives/2021/01/22/6.htm
22 Jan 2021
In eosinophilic esophagitis, budesonide orodispersible tablets maintained remission at 48 wk
While a 0.5-mg dose twice daily may be enough to maintain remission, patients with long-standing symptoms or extensive disease might benefit from a 1-mg dose twice daily, according to an ACP Journal Club commentary.
https://gastroenterology.acponline.org/archives/2021/04/23/8.htm
23 Apr 2021
In recurrent C difficile infection, oral FMT capsules have a pooled cure rate of 82% (low-quality evidence)
While the findings of a recent study are promising for oral fecal microbiota transplantation (FMT) capsules to treat patients with recurrent Clostridioides difficile infection, more well-designed trials are needed before routine use, an ACP Journal Club commentary noted.
https://gastroenterology.acponline.org/archives/2021/06/25/8.htm
25 Jun 2021